Assetmark Inc. Increases Holdings in Zoetis Inc. (NYSE:ZTS)

Assetmark Inc. increased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 36.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,004 shares of the company's stock after buying an additional 19,964 shares during the quarter. Assetmark Inc.'s holdings in Zoetis were worth $14,804,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company's stock worth $25,000 after buying an additional 89 shares in the last quarter. Independence Bank of Kentucky increased its position in shares of Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company's stock worth $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC bought a new position in Zoetis in the fourth quarter valued at about $33,000. Ramirez Asset Management Inc. bought a new position in Zoetis in the third quarter valued at about $35,000. Finally, Gladius Capital Management LP bought a new position in Zoetis in the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the business's stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, April 30th. HSBC decreased their target price on Zoetis from $230.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, May 8th. StockNews.com cut Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 20th. Piper Sandler reiterated an "overweight" rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $211.75.

Zoetis Trading Down 0.4 %

ZTS traded down $0.74 during trading on Wednesday, hitting $172.05. The company's stock had a trading volume of 1,575,459 shares, compared to its average volume of 3,075,565. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The stock's fifty day moving average price is $164.22 and its 200-day moving average price is $179.63. The firm has a market capitalization of $78.51 billion, a P/E ratio of 33.15, a PEG ratio of 2.70 and a beta of 0.86.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.31 earnings per share. Analysts anticipate that Zoetis Inc. will post 5.77 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.